(+)-epicatechin
AssetAlso called Epicatechin, Evesse EPC, +Epi
Flavanol that improves endothelial and vasodilatory function
- Stage
- Phase 2, no development reported
- Modality
- Supplement
- Target
- Not known
- 3
- Indications
- 10
- Trials
- 2
- Developers
No development reported since March 2022. Last activity: Trial NCT04386304 completed. clinicaltrials.gov
Indications
3Borderline hypertension
Phase 2, Completed, NCT01690676, clinicaltrials.gov, Oct 31, 2026
Becker muscular dystrophy
Phase 1, Completed, NCT04386304, clinicaltrials.gov, Oct 18, 2026
Age-related cognitive decline
Preclinical, doi.org, Nov 19, 2025
In the full profile
- Owner and partners2
- Trials10
- Evidence for its targets1
- Competitors2
- Aging relevance4
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.